Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2023-03-13 AGM Information
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Report of Reason for Holding a General Meeting on a Concentrated Date'. It explains why the company scheduled its shareholder meeting on a date designated as a 'concentrated date' by the KOSDAQ Association. Since this is a specific regulatory disclosure regarding corporate governance and meeting logistics that does not fit into the other specific categories like AGM-R (presentation materials) or PSI (proxy solicitation), it is classified as a general regulatory filing.
2023-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to report preliminary financial results or significant fluctuations before the final audit report is finalized. Since it provides key financial highlights and reasons for the change, it fits the definition of an Earnings Release (ER). FY 2022
2023-02-15 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (Annual General Meeting). It is under 5,000 characters and serves as a formal notice of an upcoming corporate event rather than the meeting materials themselves. Since it does not fit into specific categories like dividend announcements or proxy solicitations, it falls under the general regulatory filing category.
2022-12-16 Korean
[기재정정]주요사항보고서(유형자산양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service and Korea Exchange. It specifically details a 'Decision to Acquire Tangible Assets' (유형자산 양수 결정) and is an amendment (정정신고) to a previous filing. This type of regulatory disclosure regarding asset acquisition does not fit into specific categories like earnings releases or annual reports, and therefore falls under the general regulatory filing category.
2022-12-08 Korean
[첨부추가]주요사항보고서(유형자산양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korea Exchange (KRX) regarding the decision to acquire tangible assets (real estate). This type of filing is a mandatory regulatory disclosure for material corporate events. Since it does not fit into specific categories like M&A (which usually refers to corporate mergers/acquisitions of entities) or capital changes, and is a formal regulatory disclosure of a material event, it is best classified as a Regulatory Filing (RNS).
2022-11-30 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Abion Inc.' (에이비온 주식회사) covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.